Oligopeptide delivery carrier for osteoclast precursors.
Dendritic amine and guanidinium group-modified nanoparticles were investigated for the delivery of model peptide drug into primary osteoclast precursor cells (bone marrow macrophages; BMMs). The model peptide drug was encapsulated into the nanoparticle by dropping the drug/carrier dissolved in dimethylsulfoxide/methylene chloride cosolvent into water containing poly(vinyl alcohol) as a stabilizer. Flow cytometry and spectrofluorimetry analysis indicated that the model drug itself was not taken up by the BMMs; however, nanoparticle systems underwent significant cellular uptake. In particular, guanidinium group-modified nanoparticles were taken up more efficiently than amine group-modified ones. Cell viability studies showed that both amine and guanidinium group-modified nanoparticles exhibited no significant cytotoxicity up to 100 microg/mL against the cells.
Chi
Bo
B
Department of Chemistry and Nano Science and Division of Life and Pharmaceutical Sciences, Department of Bioinspired Science, Ewha Womans University, Seoul, Korea.
Park
So Jeong
SJ
Park
Min Hee
MH
Lee
Soo Young
SY
Jeong
Byeongmoon
B
D000588:Amines / Q000737:chemistry; D000818:Animals; D002470:Cell Survival; D002478:Cells, Cultured; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D005260:Female; D019791:Guanidine / Q000737:chemistry; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D015394:Molecular Structure; D053758:Nanoparticles / Q000737:chemistry*; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D010010:Osteoclasts / Q000166:cytology*; D010316:Particle Size
D000588:Amines; D004337:Drug Carriers; D009842:Oligopeptides; D019791:Guanidine